Nimustine (ACNU) Plus Teniposide (VM26) in Recurrent Glioblastoma]http://content.karger.com/produktedb/produkte.asp?typ=fulltext&file=000201943]Nimustine (ACNU) Plus Teniposide (VM26) in Recurrent Glioblastoma (http://content.karger.com/produktedb/produkte.asp?typ=fulltext&file=000201943)
Irgendwie klingen die Resultate nicht so berückend. Ich zitiere die Zusammenfassung: The benefit of the nimustine-teniposide combination is moderate in patients with recurrent GBM. The data support the efficacy of the nimustine-teniposide chemotherapy, but the rate of high-grade hematotoxicity is increased.